CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 70 enrolled
Drug / intervention
Chlorpromazine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03021486
NCT03021486Phase 3Active
CompareCT.gov

Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit

M.D. Anderson Cancer Center·interventional·Posted Jan 16, 2017·Updated Mar 18, 2026

In Brief

A Phase 3 clinical trial evaluating Chlorpromazine, Haloperidol, and 2 other interventions for Advanced Malignant Neoplasm and 4 related conditions. Active but no longer recruiting, targeting 70 participants across 1 site.

Detailed Summary

This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Neoplasm, Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Nursing Research (NINR)

Timeline

Phase 3Active
20172018201920202021202220232024202520262027
First PostedJan 16, 2017
Enrollment StartJun 5, 2017
Primary CompletionJun 5, 2021
Study CompletionJun 30, 2027
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 9.5 years ago

Interventions

Chlorpromazinedrug

Given IV

Haloperidoldrug

Given IV

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies